Viral vector manufacturing collaboration generates ‘tangible value’ 27-Jun-2019 By Vassia Barba & Maggie Lynch Cobra and Symbiosis announce the completion of their collaboration on viral vector development and manufacturing, supported by £1.9m Innovate UK grant.
Catalent enters AAV vector production agreement with IVERIC bio 18-Jun-2019 By Maggie Lynch Catalent is producing AAV vectors for the preclinical and clinical trial supply of Iveric bio’s lead drug candidates.
German biotech opens US office to expand its global presence 05-Feb-2019 By Maggie Lynch Sirion Biotech has opened a US-based office to support local gene therapy research and clinical development with viral vector contract manufacturing.
Brammer Bio advancing 3 year, $200m program: 700 employees expected by mid-2019 27-Sep-2018 By Melissa Fassbender Brammer Bio’s three-year, $200m investment program is set to establish more than 30 suites for both clinical and commercial viral vector supply.
